Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Depreciation & Amortization (CF) (2016 - 2025)

Fate Therapeutics' Depreciation & Amortization (CF) history spans 14 years, with the latest figure at $3.1 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 36.38% year-over-year to $3.1 million; the TTM value through Dec 2025 reached $12.9 million, down 31.97%, while the annual FY2025 figure was $12.9 million, 31.97% down from the prior year.
  • Depreciation & Amortization (CF) reached $3.1 million in Q4 2025 per FATE's latest filing, down from $3.2 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $4.9 million in Q4 2023 to a low of $959000.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $3.5 million, with a median of $3.3 million recorded in 2025.
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 187.9% in 2022, then plummeted 36.38% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $2.3 million in 2021, then soared by 114.63% to $4.8 million in 2022, then rose by 1.26% to $4.9 million in 2023, then dropped by 1.84% to $4.8 million in 2024, then tumbled by 36.38% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Depreciation & Amortization (CF) are $3.1 million (Q4 2025), $3.2 million (Q3 2025), and $3.3 million (Q2 2025).